Inhibikase Therapeutics (NYSE:IKT) Trading Down 4.9%

Inhibikase Therapeutics, Inc. (NYSE:IKT)’s share price was down 4.9% during mid-day trading on Thursday . The company traded as low as $1.15 and last traded at $1.15. Approximately 68,062 shares were traded during mid-day trading, an increase of 215% from the average daily volume of 21,591 shares. The stock had previously closed at $1.21.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered their price objective on Inhibikase Therapeutics from $27.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, May 21st.

Inhibikase Therapeutics Stock Performance

The stock has a 50 day moving average of $1.55 and a 200-day moving average of $1.89. The firm has a market capitalization of $8.31 million, a P/E ratio of -0.35 and a beta of 1.32.

Inhibikase Therapeutics (NYSE:IKT) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.06. As a group, sell-side analysts expect that Inhibikase Therapeutics, Inc. will post -1.87 EPS for the current year.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.